Abstracts tagged "Lupus nephritis"

Abstract Number: 012 • 2023 Pediatric Rheumatology Symposium
Thrombotic Microangiopathic Changes in Kidney Biopsies of Childhood-Onset Systemic Lupus Erythematous Patients with and Without Severe Hematologic Disturbances
Cathy Tsin¹, Megan Troxell¹, Vivek Charu¹, Rufei Lu² and Joyce Hsu³, ¹Stanford University, Palo Alto, CA, ²UCSF, San Francisco, CA, ³Stanford Medicine, Children's Health, Palo Alto, CA
Background/Purpose: Outcomes for pediatric patients with lupus nephritis (LN) remain suboptimal. LN may present with thrombotic microangiopathy (TMA) seen on kidney biopsy. Childhood-onset SLE patients…
Abstract Number: 005 • 2023 Pediatric Rheumatology Symposium
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study
Emily Zhang¹, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan¹, Mindy Lo¹, Olha Halyabar², Melissa Hazen¹, Ezra Cohen³, Lauren Henderson¹, Siobhan Case⁴, Margaret Chang¹, Camille Frank¹, Ankana Daga¹, Jonathan Hausmann⁵, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma¹, Mia Chandler⁶, Fatma Dedeoglu¹, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁷, Mary Beth Son¹ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Children's Hospital/Boston Medical Center, Boston, MA, ³Boston Medical Center, Boston, MA, ⁴Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁵Boston Children's Hospital / Massachusetts General Hospital, Boston, MA, ⁶Boston Children's Hospital; Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: The morbidity of chronic glucocorticoid (GC) use is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The newly developed pediatric glucocorticoid…
Abstract Number: 047 • 2023 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹, Kelly Rouster-Stevens¹⁰, Aliese Sarkissian¹¹, Julia Shalen¹², William Soulsby¹³, Marinka Twilt¹⁴, Eveline Wu¹⁵, Laura Lewandowski¹⁶, Scott Wenderfer¹⁷ and Jennifer Cooper¹⁸, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³University of Colorado, Denver, CO, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Akron Children's Hospital, Akron, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹¹UNC- Chapel Hill, Durham, NC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of California, San Francisco, San Francisco, CA, ¹⁴Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵UNC Chapel Hill, Chapel Hill, NC, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁸University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium
Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort
Sara Patrizi¹, Megha Tandel², Derek Boothroyd² and Joyce Hsu¹, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
Abstract Number: 0323 • ACR Convergence 2022
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
Nevin Hammam¹, Mohamed Bakrey Mahmoud², Aly Bakhiet³, Rasha El Owaidy⁴, Hend Abdel Nabi⁵, Ahmed M Elsaman⁶, Iman Khalifa⁷, Abeer M NourEl-Din⁸, Rawhya R ElShereef⁹, Eman Hassan¹⁰, Faten Ismail⁹, Iman I El-Gazzar¹¹, Abdelhafeez Moshrif¹², Noha M Khalil¹³, Marwa A Amer¹⁴, Hanan M Fathy¹⁵, Nancy Abdel Salam¹⁵, Samar Tharwat¹⁶, Mervat I Abd Elazeem¹⁷, Hanan M Fathi¹⁸ and Tamer A Gheita¹¹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ²Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, ⁵Pediatrics Department, Rheumatology and Nephrology Unit, Tanta University, Gharbia, Egypt, ⁶Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ⁷Pediatrics Department, Rheumatology and Nephrology Unit, Helwan University, Cairo, Egypt, ⁸Pediatrics Department, National Research Centre (NRC), Cairo, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ¹⁰Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹³Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹⁵Pediatrics Department, Rheumatology and Nephrology Unit, Alexandria University, Alexandria, Egypt, ¹⁶Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹⁷Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ¹⁸Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt
Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ…
Abstract Number: 0540 • ACR Convergence 2022
Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE
Sandra Jägerback¹, Alvaro Gomez¹ and Ioannis Parodis², ¹Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor…
Abstract Number: 0992 • ACR Convergence 2022
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Amit Saxena¹, Samir Parikh², Richard Furie³, Richard Leff⁴, Steven Hua⁴, Li Long⁵ and Noreen Henig⁴, ¹NYU School of Medicine, New York, NY, ²The Ohio State University, Columbus, OH, ³Northwell Health, Great Neck, NY, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Zetomipzomib is a first-in-class selective inhibitor of the immunoproteasome that is active in multiple autoimmune disease models, including murine models of SLE and LN.…
Abstract Number: 1478 • ACR Convergence 2022
Urine ALCAM Is a Strong Predictor of Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung¹, Cherie Ng¹, AMP SLE/RA consortium⁵, Michelle Petri⁶, Chandra Mohan⁷ and Chaim Putterman⁸, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Accelerating Medicines Partnership, Los Angeles, CA, ⁶Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁷University of Houston, Houston, TX, ⁸Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: T cells play a critical role in the pathogenicity of SLE and lupus nephritis (LN). Hence, identifying T cell co-stimulatory pathways and mediators that…
Abstract Number: 2072 • ACR Convergence 2022
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
Ilana Usiskin and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with lupus nephritis (LN) are often treated with high doses of glucocorticoids and experience glucocorticoid-related toxicity. Quantifying this toxicity may be a useful…
Abstract Number: 0331 • ACR Convergence 2022
Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value
Devyn Zaminski¹, Amit Saxena¹, Peter Izmirly², Jill Buyon² and H Michael Belmont¹, ¹NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE is characterized by autoantibody production. The most common lupus-specific serology is the anti-dsDNA antibody (anti-DNA). Traditionally, anti-DNA is measured by an enzyme immunoassay…
Abstract Number: 0541 • ACR Convergence 2022
Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Factors
Tara Tofighi, Jiandong Su and Zahi Touma, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with SLE have an increased risk of developing venous thrombo-embolism (VTE) based on several cohort studies, accounting for significant morbidity and mortality. Lupus…
Abstract Number: 1001 • ACR Convergence 2022
Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
David Isenberg¹, Celia Lin², Amy Kao³, Aida Aydemir⁴ and Caroline Gordon⁵, ¹University College London, London, United Kingdom, ²Vera Therapeutics, Inc, Burlingame, CA, ³EMD Serono, Billerica, MA, ⁴EMD Serono Research & Development Institute, Inc, Billerica, MA, ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind,…
Abstract Number: 1480 • ACR Convergence 2022
Is Lupus Podocytopathy a New Variant of Lupus Nephritis?
Clarice P. Lin¹ and Richard C. Chou², ¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, ²University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY
Background/Purpose: Kidney disease is a common manifestation of systemic lupus erythematosus (SLE); when it presents as glomerulonephritis also known as lupus nephritis (LN), it predicts…
Abstract Number: 2077 • ACR Convergence 2022
Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Background: Early complete remission (within 12 months from diagnosis) is considered an important protective factor against development of advanced chronic kidney disease (CKD) in…
Abstract Number: 0333 • ACR Convergence 2022
Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis
Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions
Background/Purpose: Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with…

1
2
3
…
25
Next Page »